Sigilon Therapeutics Stock Return On Asset

Sigilon Therapeutics fundamentals help investors to digest information that contributes to Sigilon Therapeutics' financial success or failures. It also enables traders to predict the movement of Sigilon Stock. The fundamental analysis module provides a way to measure Sigilon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sigilon Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sigilon Therapeutics Company Return On Asset Analysis

Sigilon Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Sigilon Therapeutics Return On Asset

    
  -0.24  
Most of Sigilon Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sigilon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Sigilon Therapeutics has a Return On Asset of -0.2365. This is 97.3% lower than that of the Biotechnology sector and 99.0% lower than that of the Health Care industry. The return on asset for all United States stocks is 68.93% higher than that of the company.

Sigilon Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sigilon Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sigilon Therapeutics could also be used in its relative valuation, which is a method of valuing Sigilon Therapeutics by comparing valuation metrics of similar companies.
Sigilon Therapeutics is currently under evaluation in return on asset category among its peers.

Sigilon Fundamentals

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Sigilon Stock

If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance